RE Pratley, J Rosenstock, FX Pi-Sunyer, MA … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—Mean baseline A1C and fasting plasma glucose (FPG) were significantly
lower in older (70 years: 8.3 ± 0.1% and 9.6 ± 0.1 mmol/l, respectively) than
in younger (50 years: 8.7 ± 0.0% and 10.5 ± 0.1 mmol/l, respectively) ... Cited by 20 - Related articles - BL Direct - All 5 versions
JC Chan, R Scott, JC Arjona Ferreira, D … - Diabetes Obes Metab, 2008 - interscience.wiley.com Methods: In a 54-week, randomized, double-blind, parallel-group study, patients
with baseline glycosylated haemoglobin A 1c (HbA 1c ) values of 6.5–10% were
allocated (2:1) to sitagliptin (for 54 weeks) or the sequence of placebo ... Cited by 15 - Related articles - All 3 versions
B Ahren, G Pacini, A Tura, JE Foley, A … - Hormone and metabolic research= Hormon-und …, 2007 - ncbi.nlm.nih.gov The aim of this study was to evaluate the contribution of insulin processing to
the improved meal-related B-cell function previously shown with the DPP-4
inhibitor vildagliptin. Fifty-five patients with type 2 diabetes ... Cited by 15 - Related articles - BL Direct - All 3 versions
AJ Garber, JE Foley, MA Banerji, P Ebeling, … - Diabetes Obes Metab, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 37 - Related articles - All 4 versions
- Free from Publisher J Rosenstock, JE Foley, M Rendell, M Landin … - Diabetes Care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A 12-week, double-blind, randomized,
parallel-group study comparing vildagliptin (50 mg qd) and placebo was conducted
in 179 subjects with IGT (2-h glucose 9.1 mmol/l, A1C 5.9%). Plasma levels ... Cited by 28 - Related articles - BL Direct - All 5 versions
A Schweizer, A Couturier, JE Foley, S Dejager - Diabetic Medicine, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 90 - Related articles - BL Direct - All 4 versions
R Scott, T Loeys, MJ Davies, SS Engel… - Diabetes, obesity & metabolism, 2008 - ncbi.nlm.nih.gov Efficacy and safety of sitagliptin when added to ongoing metformin therapy in
patients with type 2 diabetes. ... Scott R, Loeys T, Davies MJ, Engel SS;
Sitagliptin Study 801 Group. ... Collaborators: Darnell D, Davis T, ... Cited by 30 - Related articles - All 2 versions
[CITATION] Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to …
EM Migoya, J Miller, P Larson, M Tanen, D … - DIABETES-NEW YORK-SUPPLEMENT-, 2007 - American Diabetes Association; 1999 Cited by 30 - Related articles - BL Direct
[CITATION] New Galvus clinical data reinforces efficacy profile; safety update provided to regulatory …
AJ Bergman, J Cote, B Yi, T Marbury, SK … - Diabetes Care, 2007 - Am Diabetes Assoc Sitagliptin is an oral, once-daily, potent, and highly selective dipeptidyl
peptidase–4 inhibitor for the treatment of type 2 diabetes (1). In subjects
with normal renal function (creatinine clearance >80 ml/min), 75–80% of ... Cited by 37 - Related articles - BL Direct - All 6 versions
